Successful drug development hinges on multimillion-dollar decisions about mechanism of action, safety, dosage, and patient response. While genomics, transcriptomics, and proteomics are well-established tools in the drug development arsenal, these tools stop short of providing a real-time, definitive representation of the clinical phenotype.
Derek Solum, Ph.D., Associate Director, Product Development at United Therapeutics, and Brian Keppler, Ph.D., Director, Discovery and Translational Sciences, Metabolon, Inc., share how metabolomics has helped United Therapeutics enhance its multi-omics platform and improve decision-making across all phases of drug development.
In this talk you’ll learn:
Offered Free by: Metabolon
See All Resources from: Metabolon
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.